Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 6/20 | 0.31 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.30 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.30 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.30 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21354724 | 0.89 | EGFR (0.33) | EGFRCSNK1DCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL21354564 | 0.88 | IDH1 (0.33) | EGFRCSNK1DCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL21354707 | 0.82 | EGFR (0.37) | EGFRCSNK1DCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL29701148 | 0.82 | EGFR (0.37) | EGFRCSNK1DCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL29701147 | 0.82 | EGFR (0.37) | EGFRCSNK1DCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL21390870 | 0.79 | JAK1 (0.30) | — | |
| SCHEMBL21390872 | 0.79 | HCAR1 (0.36) | — | |
| SCHEMBL18779232 | 0.78 | EGFR (0.36) | EGFRCSNK1DCYP3A4CYP2C9CYP2D6 | |
| SCHEMBL23330295 | 0.78 | ACSS2 (0.38) | EGFRMAP3K7IRAK4 | |
| SCHEMBL21354742 | 0.78 | EGFR (0.33) | EGFRCYP3A4CYP2C9KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062389-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | BOZIK MICHAEL E (US) | 2026-03-05 | — | — | US | disclosed |
| US-12286408-B2 | KV7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-04-29 | — | — | US | disclosed |
| US-20240002349-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2024-01-04 | — | — | US | disclosed |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2023-01-05 | — | — | US | disclosed |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2023-01-05 | — | — | US | disclosed |
| US-11261162-B2 | KV7 channel activators compositions and methods of use | KNOPP BIOSCIENCES, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KNOPP BIOSCIENCES LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KNOPP BIOSCIENCES LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2019-09-19 | — | — | US | disclosed |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261162-B2 | KV7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | EGFR 4338/4885CSNK1D 646/4885CYP3A4 2565/4885 |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | EGFR 4338/4885CSNK1D 646/4885CYP3A4 2565/4885 |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | EGFR 4338/4885CSNK1D 646/4885CYP3A4 2565/4885 |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | EGFR 4338/4885CSNK1D 646/4885CYP3A4 2565/4885 |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | EGFR 4338/4885CSNK1D 646/4885CYP3A4 2565/4885 |
| US-20260062389-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNH3, KCNA3 | EGFR 2207/4885CSNK1D 329/4885CYP3A4 1190/4885 |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | EGFR 4338/4885CSNK1D 646/4885CYP3A4 2565/4885 |
| US-12286408-B2 | KV7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | EGFR 4338/4885CSNK1D 646/4885CYP3A4 2565/4885 |
| US-20240002349-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | EGFR 4338/4885CSNK1D 646/4885CYP3A4 2565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.